Lemborexant: Mechanism of Action and Clinical Profile of a Dual Orexin Receptor Antagonist

　　Lemborexant is a novel dual orexin receptor antagonist(DORA),representing one of the most landmark innovative therapies in the field of sleep medicine in recent years.Unlike traditional benzodiazepines or Z-drugs that induce sleep by boosting the inhibitory effect of the GABA system,lemborexant works by blocking the binding of orexin A and orexin B to their receptors OX1R and OX2R,thereby downregulating the sustained activation of central wakefulness signals and restoring the sleep-wake rhythm to balance in a more natural fashion.

　　In terms of therapeutic efficacy,lemborexant is primarily indicated for improving sleep onset difficulty and sleep maintenance disturbance.The orexin system is one of the core neural pathways that maintain human wakefulness.When this system remains in a chronically hyperactivated state,patients with insomnia often develop chronic symptoms such as delayed sleep onset,frequent nocturnal awakenings and early morning awakening.By selectively inhibiting this wakefulness pathway,lemborexant facilitates a gradual transition of the brain from a state of excessive wakefulness drive to a stable sleep state.Its effect is therefore better defined as"sleep structure regulation"rather than simple sedation.

　　From a clinical perspective,the drug delivers notable improvements in sleep continuity,with particular advantages in reducing the number of nocturnal awakenings,prolonging total sleep time and enhancing perceived sleep quality.Meanwhile,since its mechanism does not directly amplify the effect of central inhibitory neurotransmitters,it exerts a milder impact on deep sedation and respiratory depression compared with conventional sedative-hypnotics.This is the core reason it is classified as a mechanism-innovative sleep aid in global sleep medicine practice.

　　That said,lemborexant is still associated with a well-defined adverse reaction profile.In terms of safety,commonly reported adverse events include somnolence,dizziness,fatigue and next-day residual sleepiness.This"morning residual effect"is mostly related to individual metabolic rate and the process of sleep cycle adjustment.Some patients may experience subjective symptoms such as intensified dreaming or altered sleep architecture during the initial treatment phase,which is directly linked to the role of the orexin system in regulating REM sleep.In addition,reduced attention or prolonged reaction time may occur in rare cases,requiring special caution for individuals in occupations demanding high alertness.

　　From the perspective of mechanism-related side effects,since lemborexant targets the wakefulness regulatory system,its core risk is not respiratory depression or severe neurological suppression as seen with traditional agents,but rather a"prolonged wakefulness delay effect"—a certain degree of residual sleepiness that may persist into the early morning.This phenomenon usually partially resolves with continuous use,yet remains closely associated with dosage and individual sensitivity.

　　Overall,the core value of lemborexant lies in inducing sleep in a more physiological manner by modulating the orexin system,leading to a more natural sleep architecture.Its side effects are predominantly related to delayed central wakefulness regulation,rather than the deep inhibitory effects of traditional sedative agents.